{
    "organizations": [],
    "uuid": "7955e98aa0a3cbed9338427540326b645cc96bb9",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-biomarin-announces-first-patient-d/brief-biomarin-announces-first-patient-dosed-in-phase-1-2-study-of-treatment-for-type-of-hemophilia-a-idUSFWN1SM0YV",
    "ord_in_thread": 0,
    "title": "BRIEF-Biomarin Announces First Patient Dosed In Phase 1/2 Study Of Treatment For Type of Hemophilia A",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 15 (Reuters) - Biomarin Pharmaceutical Inc:\n* BIOMARIN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1/2 STUDY EVALUATING VALOCTOCOGENE ROXAPARVOVEC GENE THERAPY IN SEVERE HEMOPHILIA A PATIENTS WITH PRE-EXISTING AAV5 ANTIBODIES Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles. ",
    "published": "2018-05-15T20:39:00.000+03:00",
    "crawled": "2018-05-16T18:58:58.023+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "biomarin",
        "pharmaceutical",
        "inc",
        "biomarin",
        "announces",
        "first",
        "patient",
        "dosed",
        "phase",
        "study",
        "evaluating",
        "valoctocogene",
        "roxaparvovec",
        "gene",
        "therapy",
        "severe",
        "hemophilia",
        "patient",
        "aav5",
        "antibody",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}